Loading clinical trials...
Loading clinical trials...
A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcƔRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy
Conditions
Interventions
BI-1206 single agent dose escalation phase
Combination of BI-1206 with rituximab escalation phase
+2 more
Locations
5
United Kingdom
Leicester Royal Infirmary
Leicester, England, United Kingdom
Christie Hospital
Manchester, England, United Kingdom
Oxford Cancer and Haematology Centre, Churchill Hospital
Oxford, England, United Kingdom
Derriford Hospital
Plymouth, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Start Date
October 27, 2016
Primary Completion Date
March 19, 2020
Completion Date
March 19, 2020
Last Updated
July 8, 2021
NCT05139017
NCT05006716
NCT06026319
NCT01804686
NCT05442515
NCT05755087
Lead Sponsor
Cancer Research UK
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions